| Issue |
J Oral Med Oral Surg
Volume 29, Number 4, 2023
|
|
|---|---|---|
| Article Number | 41 | |
| Number of page(s) | 10 | |
| DOI | https://doi.org/10.1051/mbcb/2023046 | |
| Published online | 02 February 2024 | |
Systematic Review
Posaconazole as single or adjunctive antifungal in mucormycosis of the maxilla: systematic review and meta-analysis
Department of Oral and Maxillofacial Surgery, Government Dental college and Hospital, Nagpur, Hanuman Nagar, Medical Chowk, Nagpur, Maharashtra 440003, India
* Correspondence: arwapardiwala22@gmail.com
Received:
30
August
2023
Accepted:
29
November
2023
Introduction: The aim of this systematic review was to analyse the benefits of utilizing posaconazole as a single drug therapy or in combination with other antifungals for the treatment of maxillary mucormycosis as opposed to sole use of amphotericin B. Materials and methods: Databases (MEDLINE via PubMed, Cochrane, EBSCO-host, Scopus, Science Direct, Clinical Trial Registry- India (CTRI) and Google scholar), review articles were searched from 1997 to 2022, using various MeSH terms.
Results: After application of the inclusion and exclusion criteria, four articles were finally selected. Three-month survival rate and duration of hospital stay were analysed as primary outcomes. There was no difference in survival among cases of maxillary mucormycosis treated with either drug alone. Death reported after treatment with combination treatment was less as compared to that with amphotericin B alone; however, there was non-significant difference in survival among cases treated with posaconazole in addition to amphotericin B or amphotericin B alone. Conclusion: Posaconazole can be used a single drug therapy for the treatment of maxillary mucormycosis due to its benefits outweighing its risks. The limitations of this study are the paucity of studies and Randomized Controlled Trials available in the literature in this field of study.
Key words: Posaconazole / amphotericin / maxillary mucormycosis
© The authors, 2023
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.